New York State Common Retirement Fund Has $1.74 Million Position in LivaNova PLC (NASDAQ:LIVN)

New York State Common Retirement Fund lifted its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 122.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 37,557 shares of the company's stock after acquiring an additional 20,699 shares during the period. New York State Common Retirement Fund owned approximately 0.07% of LivaNova worth $1,739,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of LIVN. Point72 Asset Management L.P. grew its position in LivaNova by 62.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company's stock worth $109,914,000 after purchasing an additional 806,374 shares during the last quarter. Point72 DIFC Ltd lifted its stake in shares of LivaNova by 75,799.6% in the third quarter. Point72 DIFC Ltd now owns 181,400 shares of the company's stock valued at $9,531,000 after buying an additional 181,161 shares during the period. The Manufacturers Life Insurance Company grew its position in LivaNova by 286.4% during the third quarter. The Manufacturers Life Insurance Company now owns 207,248 shares of the company's stock worth $10,889,000 after buying an additional 153,611 shares in the last quarter. Victory Capital Management Inc. increased its stake in LivaNova by 16.6% during the third quarter. Victory Capital Management Inc. now owns 935,102 shares of the company's stock valued at $49,130,000 after acquiring an additional 133,401 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in LivaNova by 17.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company's stock valued at $32,678,000 after acquiring an additional 93,311 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

LIVN has been the topic of several recent research reports. Wolfe Research lowered LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. StockNews.com downgraded shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, February 26th. Stifel Nicolaus lowered their price target on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Needham & Company LLC reduced their price objective on shares of LivaNova from $75.00 to $64.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group lowered their target price on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Monday. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, LivaNova presently has an average rating of "Buy" and a consensus target price of $62.20.

LivaNova Price Performance

Shares of NASDAQ LIVN traded down $1.11 during midday trading on Thursday, reaching $39.77. 294,838 shares of the company traded hands, compared to its average volume of 579,433. The stock's 50-day simple moving average is $47.08 and its 200-day simple moving average is $49.43. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova PLC has a 12 month low of $39.90 and a 12 month high of $64.47. The firm has a market cap of $2.16 billion, a PE ratio of 94.63 and a beta of 1.10.

Insider Activity at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the company's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the sale, the director now directly owns 7,522 shares of the company's stock, valued at approximately $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is currently owned by insiders.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.